Indivior Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Indivior Pharmaceuticals, Inc. (formerly Indivior PLC, which completed its corporate redomiciliation from the United Kingdom to the United States in January 2026) is a global leader in specialty pharmaceuticals focused on substance use disorders, particularly opioid use disorder (OUD), overdose reversal, and serious mental illness. The company's primary commercial driver is Sublocade, a once-monthly buprenorphine extended-release injection. Its portfolio also includes Suboxone sublingual film, Perseris for schizophrenia, and Opvee nasal spray for opioid overdose reversal. Indivior operates primarily in the United States, which represents its largest market, while maintaining selective international operations.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A multi-year operational roadmap focused on accelerating U.S. SUBLOCADE dispense unit growth and net revenue throughout 2026, while growing adjusted EBITDA and cash flow at a significantly faster rate than net revenue.
Expected impact: Aims to drive SUBLOCADE dispense unit growth to the mid-teens and expand adjusted EBITDA margins to approximately 51% in 2026.
An initiative launched under Phase I of the Action Agenda to simplify the organization by eliminating non-essential activities, reducing headcount, consolidating the real estate footprint, and optimizing the Rest of World (ROW) business.
Expected impact: Delivers at least $150 million in annual non-GAAP operating expense savings beginning in 2026, reducing projected operating expenses to a range of $430 million to $450 million.
The restructuring of the corporate parent entity to change its domicile from the U.K. to the U.S. under a court-approved scheme of arrangement, establishing Delaware-incorporated Indivior Pharmaceuticals, Inc. as the ultimate parent.
Expected impact: Maximizes the benefits of its U.S. stock listing, expands capital markets presence, increases potential U.S. equity indexation, and simplifies corporate governance.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire Opiant's pipeline of addiction treatment and overdose reversal candidates, notably OPVEE (nalmefene) nasal spray, to diversify Indivior's portfolio.
Financial impact: Contributed to the company's strategic pivot and subsequent restructuring charges in 2025.
Strategic Partnerships
Five agreements executed in Q1 2026 to improve commercial dispense yields and streamline the distribution of SUBLOCADE.
Terms: Specific financial terms were not disclosed.